Welcome to the upgraded MacSphere! We're putting the finishing touches on it; if you notice anything amiss, email macsphere@mcmaster.ca

Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018

Thumbnail Image

Files

Oseltamivir for coronavirus illness post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial i.pdf (111.71 KB)

Date

2020-07

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Royal College of General Practitioners

Abstract

<jats:sec><jats:title>Background</jats:title><jats:p>Patients infected with the novel coronavirus (SARS-CoV-2) are being treated empirically with oseltamivir, but there is little evidence from randomised controlled trials to support the treatment of coronavirus infections with oseltamivir.</jats:p></jats:sec><jats:sec><jats:title>Aim</jats:title><jats:p>To determine whether adding oseltamivir to usual care reduces time to recovery in symptomatic patients who have tested positive for coronavirus (not including SARS-CoV-2).</jats:p></jats:sec><jats:sec><jats:title>Design and setting</jats:title><jats:p>Exploratory analysis of data from an open-label, pragmatic, randomised controlled trial during three influenza seasons, from 2016 to 2018, in primary care research networks, in 15 European countries.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>Patients aged ≥1 year presenting to primary care with influenza-like illness (ILI), and who tested positive for coronavirus (not including SARS-CoV-2), were randomised to usual care or usual care plus oseltamivir. The primary outcome was time to recovery defined as a return to usual activities, with minor or absent fever, headache, and muscle ache.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Coronaviruses (CoV-229E, CoV-OC43, CoV-KU1 and CoV-NL63) were identified in 308 (9%) out of 3266 randomised participants in the trial; 153 of these were allocated to usual care and 155 to usual care plus oseltamivir; the primary outcome was ascertained in 136 and 147 participants, respectively. The median time to recovery was shorter in patients randomised to oseltamivir: 4 days (interquartile range [IQR] 3–6) versus 5 days (IQR 3–8; hazard ratio 1.31; 95% confidence interval = 1.03 to 1.66; <jats:italic>P</jats:italic> = 0.026).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Primary care patients with ILI testing positive for coronavirus (not including SARS-CoV-2) recovered sooner when oseltamivir was added to usual care compared with usual care alone. This may be of relevance to the primary care management of COVID-19.</jats:p></jats:sec>

Description

Keywords

COVID-19, Europe, coronavirus, oseltamivir, primary care, randomised controlled trial, Adolescent, Adult, Aged, Antiviral Agents, COVID-19, Child, Coronavirus Infections, Drug Therapy, Combination, Europe, Female, Fever, Headache, Humans, Influenza, Human, Male, Middle Aged, Oseltamivir, Pandemics, Pneumonia, Viral, Time Factors, Treatment Outcome, Young Adult

Citation

URI

http://hdl.handle.net/11375/26508

Collections

Faculty Publications (via McMaster Experts)

Endorsement

Review

Supplemented By

Referenced By

Creative Commons license

Attribution - CC BY This Creative Commons license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. Recommended for maximum dissemination and use of licensed materials.
Except where otherwised noted, this item's license is described as Attribution - CC BY This Creative Commons license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. Recommended for maximum dissemination and use of licensed materials.